Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(12): e15631.
Published online Dec 29, 2010. doi:  10.1371/journal.pone.0015631
PMCID: PMC3012067

Both Viremia and Cytokine Levels Associate with the Lack of Severe Disease in Secondary Dengue 1 Infection among Adult Chinese Patients

Esper Georges Kallas, Editor

Abstract

Secondary dengue infections are frequently associated with increased risk for dengue hemorrhagic fever and dengue shock syndrome. Surprisingly, we observed no dengue hemorrhagic fever cases among 353 hospitalized dengue-infected patients including 212 with primary, and 141 with secondary dengue 1 infection in China. To explore virological and immunological mechanisms which may account for this unexpected clinical observation, we assessed dengue viremia, type I interferon and inflammatory cytokine levels in these patients. While the levels of viremia and inflammatory cytokines are indistinguishable between primary and secondary infections, IFNα levels are significantly higher in primary than that in secondary infection. However, IFNα levels are positively correlated with dengue viremia levels (p<0.0001), but negatively correlated with the platelet counts (p<0.0001) and serum ALT levels (p = 0.0003). These results provide direct in vivo evidence that clinical dengue disease severity is affected by both viral and human immune factors.

Introduction

Dengue viruses cause dengue fever in 50–100 million people annually, but only a small fraction of infections develop into dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS). Some favor the idea that DHF/DSS are the result of immunopathology caused by cross-reactive responses of T cells or B cells [1], [2]; others place a greater emphasis on viral virulence factors [3][5]. It may be that both immune and viral factors affect the clinical outcome of dengue fever. Nonetheless, direct evidence on the relative contributions of immune and viral elements to dengue disease severity is lacking, especially in adult patients. In this study, we built on our previous observation that DHF/DSS cases were absent among 353 hospitalized Chinese patients with either primary or secondary dengue 1 infection (DENV1) [6] to explore the possible virological and immunological mechanisms that influence dengue disease severity.

Among immune factors, we focused on type I interferons, IFNα and IFNβ (IFNα/β), and a selective number of inflammatory and anti-inflammatory cytokines. IFNα/β are often secreted rapidly upon viral infection and provide the first-line of defense for uninfected cells through the induction of an antiviral state [7][9]. In patients with dengue virus infection, IFNα serum levels are elevated early [10], [11], suggesting it may contribute to virological control in vivo. In cell cultures in vitro and murine models in vivo, IFNα and IFNβ suppress early stages of dengue viral replication; whereas the type II interferon, IFNγ (produced mainly by activated T and NK cells), limits dengue viral replication at later stages [12][16]. IFNα and IFNβ can be induced by dengue virus infection in many cell types, but the kinetics of their induction differs. IFNβ gene activation is induced within hours of dengue viral infection in A549 lung carcinoma cell lines and Chang Liver cells [17]. In contrast, IFNα secretion is detected in dengue-infected primary human monocytes and plasmacytoid dendritic cells only 20 to 24 hours post virus inoculation [18][20]. While both IFNα and IFNβ have anti-dengue activity in vitro, previous clinical studies had limited to the measurement of IFNα levels, and most had been performed in subjects with either DENV2 or DENV3 infections [10], [11], [21]. In the current study, we performed, for the first time, a large-scale measurement of both IFNα and IFNβ in patients with DENV1 infection.

Cytokines that are undetectable in the blood of healthy individuals are elevated in dengue-infected patients, such as IL-1β, IL-2, IL-6, IL-8, IL-10, IL-13, IL-18, IFNγ, TNFα, and MCP1 [22][30]. Some of them are associated more closely with DHF/DSS than others. In comparison to those with uncomplicated dengue fever, patients with DHF/DSS have higher plasma levels of inflammatory cytokines IL-6, IL-8, and TNFα [25], [31][33], and both IL-8 and TNFα levels are independent correlates of dengue disease severity [24], [32]. The anti-inflammatory cytokine IL-10 has also been reported as having higher levels in DHF/DSS patients than patients with dengue fever [21], [29], [34]. In the current study, we chose to examine in detail the correlation between these host factors and viremia levels in vivo.

Materials and Methods

Study subjects and samples

The patient cohort has been described in details previously [6]. Briefly, sera or plasma samples were obtained from 353 hospitalized patients with acute DENV1 infection during a dengue outbreak in southern China in 2006. Dengue IgM and IgG capture ELISA kits (Panbio, Brisbane, Queensland, Australia) were used to diagnose primary and secondary dengue infections according to the manufacturer's protocol. Primary infection was diagnosed when only anti-dengue IgM was positive. Secondary dengue infection was diagnosed when both anti-dengue IgM and IgG were positive and IgM/IgG ratio<1.78, or when only IgG was positive and IgG level>22 units. By these diagnostic criteria, there were 212 patients with primary and 141 with secondary infections in our clinical cohort. Excluding those with HBV co-infections which account for about 8% of the total subjects [6], 170 patients with primary infection, and 115 patients with secondary infection were included in the current study. Sera from 37 healthy control adults were also collected. In 136 dengue-infected patients in whom extra serum samples were still available at the beginning of the current study, additional virological immunological analyses were performed. These studies have been approved by the Guangzhou 8th People's Hospital Ethics Committee review. Written informed consents were obtained from all study subjects. National rules and regulations on human subject protection were strictly followed.

Clinical and laboratory tests

Routine clinical tests including platelet count, liver function tests including aspartate aminotransferase (AST) and alanine transaminase (ALT) were performed as we previously described [6]. Serum interferon levels were measured using commercially available ELISA kits for IFNα (PBL InteferonSource, Piscataway, NJ) and IFNβ (Fujirebio Diagnostics, Inc., Malvern, PA) according to the manufacturer's instructions. The human IFNα multi-subtype ELISA kit detects 14 out of 15 known human IFNα subtypes (IFN-α1, IFN-α2, IFN-α4a, IFN-α4b, IFN-αA, IFN-αB2, IFN-αC, IFN-αD, IFN-αG, IFN-αH, IFN-αI, IFN-αJ1, IFN-αK, and IFN-αWA) with a lower limit of detection of 12.5 pg/ml. Human Interferon-β ELISA kit detects IFNβ with a lower limit of detection of 2.5 IU/ml. Serum cytokine levels for IL-6, IL-10, IFNγ, and TNFα were measured using commercially available ELISA kits (Diaclone, Besancon Cedex, France) according to the manufacturer's instructions.

Quantification of viral RNA

Viral RNA was extracted from plasma sample using QIAamp Viral RNA Mini kit (QIAGEN) and transcribed into cDNA using TakaRa PrimeScript™ RT kit (TakaRa Biotech. Ltd., Da Lian city, China. www.takara.com.cn). Real-time PCR assay was then performed using TakaRa Premix Ex Taq™ (TakaRa Biotech. Ltd.) on an ABI7300 real-time PCR system (ABI, Foster city, CA). The primer and probe sequences were designed based on DENV1 isolated in Guangzhou (GenBank Accession #EU280167). The primers used were as follows: forward primer, 5′AAGGACTAGAGGTTAGAGGAGACCC3′ (nucleotides 10589 to 10613); reverse primer, 5′ CGTTCTGTGCCTGGAATGATG 3′ (nucleotides 10697 to 10677); and probe, FAM-5′ TCTGGTCTCTCCCAGCGTCAATATGCTGTT 3′-TAMRA (nucleotides 10657 to 10628) (where FAM is the reporter and TAMRA is the quencher). cDNA synthesis was performed in a total volume of 10µl containing 2µl of 5×PrimeScript buffer, 0.5µl of PrimeScript RT enzyme MixI, 2µl of random hexamer (100µM), 0.5µl of Oligo dT primer (50µM ), 2µl of viral RNA, and 3µl of RNase free dH2O. The RT conditions were 37° for 15m, followed by 85° for 5s. The PCR reaction was performed in a total volume of 20µl containing 10µl of 2×Premix Ex Taq, 0.4µl of forward primer (10µM), 0.4µl of reverse primer (10µM), 0.8µl of Probe (5µmol/L), 0.4µl of 50×ROX reference dye, 2µl of cDNA, and 6µl of RNase free dH2O. The PCR conditions were 95° for 30 s, followed by 40 cycles of 95° for 5s and 60° for 31s. A standard curve was established using a 10-fold serial dilution of plasmid DNA containing 103 to 109 copies of DENV1 genome. The lower limit of detection is 100 copies/ml. The viremia level of each patient sample was calculated according to the standard curve.

Statistical analysis

Statistical analyses were performed using GraphPad Prism Version 4.0 (GraphPad Software, San Diego, CA). One-way analysis of variance (ANOVA) was used for mean comparison from multiple groups. Association between two laboratory outcomes was analyzed by Spearman rank correlation coefficient. A statistical test with P-value<0.05 was considered significant in mean comparison, or in correlation analysis.

Results

Clinical characteristics of patients with primary and secondary DENV1 infections

Excluding those with HBV-co-infections and those with incomplete clinical or laboratory data, 285 dengue-infected patients were included in this analysis. Among these patients, 170 and 115 had primary and secondary dengue infections, respectively. Key demographic characteristics of these two patient groups were summarized in Figure 1. Patients with secondary infection are older than those with primary infections (41.3±16.6 years vs. 33.2±15.6 years, p<0.0001, Fig. 1a) and have fever for a longer period of time (5.4±1.9 days vs. 4.8±1.8 days, p = 0.0216, Fig. 1b). This might due to the fact that adults usually do not go to hospital at the beginning of their illness, so samples were collected from them later than from younger patients, and older patients are more likely to have experienced dengue infection previously than younger patients. It is interesting to note that while the platelet counts were not different between the two groups (76.1±52.6×103 /ml vs. 83.0±52.2×103 /ml, p = 0.1483, Fig. 1c), the average prothrombin time (PT) was shorter in those with secondary infection (11.25±0.83 s vs.11.81±1.36 s, p = 0.0003, Fig. 1d). Both patient groups have higher AST (primary: 106.5±94.1 U/L; secondary: 104.1±76.0 U/L) and ALT (primary: 73.4±83.0 U/L; secondary: 77.6±65.6 U/L) levels than healthy uninfected controls (AST: 24.2±5.2 U/L; ALT: 20.6±8.2 U/L, p<0.001), but similar levels to each other (Fig. 1e, f).

Figure 1
Demographic and clinical characteristics of patients with primary and secondary DENV1 infections.

Immunological and viralogical features of patients with primary and secondary DENV1 infections

To examine what else might be different between primary and secondary DENV1 infections, we next assessed the secretion of type I interferons and a selective number of inflammatory and anti-inflammatory cytokines in these patients. Figure 2 shows that all dengue infected patients had secreted higher levels of IFNα than uninfected healthy controls (primary: 18.5 (0.0~2392) pg/ml; secondary: 5.7 (0~751.7) pg/ml, vs. control: 0 (0~8.7) pg/ml, p<0.0001) and patients with primary infection had significantly higher IFNα levels than those with secondary infection (p<0.01) (Fig. 2a). In contrast, few infected subjects made substantial amounts of IFNβ (primary: 0.0(0~199.2) IU/ml; secondary: 0.0(0.0~104.3) IU/ml) and the IFNβ levels are not statistically higher than that in uninfected controls (control: 0.0(0.0~158.4) IU/ml) (Fig. 2b). While patients with both primary and secondary infections produced large amounts of inflammatory cytokines including IFNγ, TNFα and IL-6 than uninfected controls (p<0.001), there are no differences between the two patient groups (Fig. 2c, d, e); the same holds true for the anti-inflammatory cytokines, IL-10 (Fig. 2f).

Figure 2
Distinctive patterns of cytokine production in patients with primary and secondary DENV1 infections.

In patients who had an additional vial of plasma sample available after all other clinical and immunological assays were performed, we also measured viremia levels using real-time quantitative PCR as described in the Materials and Methods. These include 79 patients with primary and 57 patients with secondary infection. Results show a lack of difference in viremia levels between the two patient groups (primary: 2.05×103(1.10×102~1.57×107) copies/ml; secondary: 1.08×103(1.41×102~8.80×106) copies/ml p = 0.1170, Fig. 3). Further analysis of the association between viremia levels and fever onset days (fever onset day is defined as the duration from the time when patients first experienced fever symptom to the time when they were hospitalized and samples were collected) showed that in both patient groups, viremia levels rapidly decreased within 8 days of fever onset when analyzed together (Fig. 4c) or separated into two subsets with either primary or secondary infections (Fig. 4a, b).

Figure 3
Lack of difference in viremia levels between patients with primary and secondary DENV1 infections.
Figure 4
Rapid viremia decay in both primary and secondary DENV1 infections.

IFNα levels are associated with multiple facets of dengue disease

To gain further insight into the interpretation of various clinical and laboratory measurements obtained, we performed Spearman correlation analysis on a number of parameters that could theoretically affect disease severity. Unexpectedly, we found viremia levels to be positively correlated with the levels of antiviral cytokine IFNα either for the entire group of 136 patients (r = 0.6446, p<0.0001, Fig. 5c), or two subsets with primary ( = 79) and secondary (n = 57) infections (Fig. 5a, b). This positive correlation becomes more significant when only those with viral load greater than 1,000 copies/ml were included in the analysis (primary = 51, secondary = 29, total = 80, r = 0.7733, p<0.0001, data not shown). Also unexpected was that the IFNα levels were negatively correlated with platelet counts (r = −0.2327, P<0.0001, Fig. 6a). In addition, IFNα levels were negatively correlated with serum ALT levels (r = −0.2112, P = 0.0003, Fig. 6b), but not with AST levels (Fig. 6c).

Figure 5
Positive correlation between viremia and IFNα levels in both primary and secondary DENV1 infections.
Figure 6
Levels of IFNα were negatively correlated with platelet counts and serum ALT levels.

Temporal secretion of IFNα, IFNγ, and IL-10 during dengue fever

We and other have found that many cytokines that are undetectable in the blood of healthy individuals are significantly elevated in dengue-infected patients [6], [22][30]. The interplay between type I interferons and these other cytokines may affect the clinical outcome of dengue disease. Because only IFNα was measurable at high levels in a large proportion of DENV1-infected subjects, and IFNβ was mostly undetectable, we next analyzed the kinetics of IFNα secretion in association with that of a pro-inflammatory cytokine, IFNγ, and an anti-inflammatory cytokine, IL-10. Figure 7 shows a cross-sectional analysis between fever onset days and the median cytokine levels (left Y-axis), as well as the proportion of subjects who had a detectable level of cytokine responses in all 285 of DENV1-infected patients (right Y-axis). The median of IFNα level (182pg/ml) peaked on day 2 after fever onset and then decreased rapidly. Likewise, the percentage of patients who had low but detectable levels of IFNα (≥12.5pg/ml) was high on day 0 (within the first 24 hours of fever onset) (67%) and reached peak level on day 3 (84%) (Fig. 7a). The elevation of IFNγ levels followed the induction of IFNα and reached its peak level on days 3–4. In parallel, most subjects had detectable IFNγ on days 5–6 (Fig. 7b). In contrast, the IL-10 response only reached peak level by day 6 (142pg/ml), although a large proportion of subjects had detectable IL-10 secretion between days 2–6, an indication that IL-10 producers might be biologically more heterogeneous in the context of dengue viral infection (Fig. 7c). The same pattern of early IFNα secretion and late IL-10 production also holds true when similar analyses were performed by using patients with primary and secondary dengue infections separately (Fig.S1).

Figure 7
Temporal secretion of IFNα, IFNγ, and IL-10 during dengue fever.

Discussion

Both IFNα and IFNβ have anti-dengue activity in cell cultures in vitro and in animal models in vivo. However, previous clinical studies have only examined IFNα levels in the context of either DENV2 or DENV3 infections [10], [11], [21]. In the current study, by carefully measuring both IFNα and IFNβ levels in a large cohort of DENV1-infected adult patients, we found, for the first time, that IFNα levels are more significantly elevated than IFNβ during dengue fever. Moreover, in individuals with DENV1 infection, the IFNα elevation appears early, followed by the induction of a pro-inflammatory cytokine IFNγ, and lastly an anti-inflammatory cytokine IL-10. Unexpectedly, the levels of IFNα are directly proportional to viremia levels and the degree of thrombocytopenia.

A differential induction of IFNα and IFNβ in patients with dengue fever has never been reported before. This phenomenon is similar to that of acute HIV infection during which IFNα but not IFNβ level was rapidly, and transiently, elevated [35]. The exact reason for why only IFNα was made substantially in dengue and HIV-infected patients is not known, but it may be related to the fact that IFNα and IFNβ are produced by different cell types. IFNα is mainly produced by lymphoid cells, while IFNβ is made primarily by non-lymphoid cells. Since the principal dengue target cells are monocytic cells including monocyte, macrophage and dendritic cells [36][38] and HIV infects macrophage and CD4+ T cells, it may be expected that dengue and HIV infections directly stimulate relevant human cells to make IFNα, but not IFNβ. Nonetheless, IFNβ may be secreted subsequent to immune activation through either IFNα or other yet to be identified factors during viral infections. It is interesting to note that the temporal sequence of cytokine secretion is also similar between acute dengue and acute HIV infections, in that IFNα is made first, followed by the secretion of inflammatory cytokines, and lastly the anti-inflammatory cytokine IL-10 [35].

A significant increase in IFNα levels may contribute to the efficient control of dengue virus replication, but may also exert undesirable immune-regulatory effects on successive immune responses and thus play a more complex role in the pathogenesis of dengue fever. Unexpectedly, we observed that levels of IFNα were negatively correlated with platelet counts but positively correlated with viremia levels. These results suggest that elevated IFNα might be one of the factors contributing to decreased platelet counts during the course of the dengue fever. The regulation of platelet count during dengue virus infection is clearly due to multiple factors. For instance, it has been reported that IFNα2b could induce thrombocytopenia through the inhibition of platelet production from human megakaryocytes [39]. Our current finding may help to explain why patients with DHF have higher levels of IFNα than those with dengue fever [10]. In this regard, it is worth noting that persistent activation of IFNα gene in human peripheral blood mononuclear cells by another arbovirus, chikungunya, correlates with chronic disease [40], [41], and plasma viral loads and IFNα levels are directly proportional in chikungunya virus infected adults [42].

It is paradoxical that antiviaral IFNα levels shoud have a postitive correlation with viremia levels in vivo. This highlights the intricate interactions between a host immune factor and dengue viral replication. Although the precise reason for this is unclear, the time of sample collection may determine what type of correlations will be observed. In an experimental dengue infection system, we detected IFNα/β secretion immediately after virus production in DENV2-infected primary human monocytes, however, the kinetics of IFNα/β secretion was temporally associated with the decrease of virus production over a 5 day period (Kou, Virology, in press). A similar temporal association between viremia and IFNα secretion has also been reported in DENV3-infected Thai children [11]. Thus, our data offer a snap-shot of the dynamic interactions between dengue viral replicaiton and IFNα-mediated host defense mechanisms, and should not be interpreted as IFNα does not control virus replication.

It is interesting to note that IFNγ, IL-6 and IL-8 levels were found to be higher in secondary than primary infections in a recent study of dengue-infected patients in Western India [43]. In our current study, none of the cytokines measured including IFNγ, TNFα, IL-6 and IL-10 were statistically significantly different between patients with primary and secondary infections. The contrasting results may be explained by variability in dengue serotypes and the timing of sample collection. Our patients were homogeneous with DENV-1 infection and without DHF, whereas their patients were infected by all 4 DENV serotypes and a third of whom had DHF. Additionally, a large number of patients in our cohort had cytokine levels in the range of hundreds to thousands (pg/ml) because we enrolled most patients early after the onset of symptoms, whereas the majority of their patients had cytokine levels in the tens and a few of them in the hundreds (pg/ml) because nearly half of their patients were recruited late after the onset of illness [43]. Moreover, it is possible that the genetic differences between the Indian and Chinese populations have contributed to the observed discrepancy between these two studies.

In summary, we compared the levels of viremia, IFNα/β, and a selective number of cytokines in a large cohort of acutely DENV1 infected patients with either primary or secondary infection. Our results suggest that a lack of severe disease in this cohort of secondary DENV1 infected adults could be explained in part by both immune and virologic factors. It may also be possible that unique viral factors such as virus strain or genetic factors such as HLA alleles in the population could affect clinical presentation significantly. These should be focus of future studies. Overall, our findings not only advanced the understanding of human dengue pathophysiology, but also had implication in developing new anti-dengue therapeutics.

Supporting Information

Figure S1

Temporal secretion of IFNα, IFNγ, and IL-10 in patients with dengue fever. The associations between fever day and cytokine secretion including IFNα (a, b) IFNγ (d, e), and IL-10 (g, h) were analyzed in either in 170 subjects with primary dengue infection (a, d, g), in 115 subjects with scondary dengue infection (b, e, h). The dashed line represents the median of cytokine levels, and the solid line indicates the percentage of subjects who had a detectable cytokine level. Each symbol represents the median or average value at indicated time point.

(TIF)

Acknowledgments

We thank Maria Arévalo for editorial assistance.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: The study was supported in part by research grants from Guangdong province Natural Science Foundation (grant#1015100600200001 to FCZ) and Guangdong province Science and Technology Program (grant#2007A032100004 to XPT). The funders provided these grants to cover the supply cost of the current study. But the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Halstead SB. Immunological Parameters of Togavirus Disease Syndromes. In: Schlesinger RW, editor. The Togaviruses - Biology, Structure, Replication. New York: Academic Press; 1980. pp. 107–73.
2. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology. 1999;25;257(1):1–6. [PubMed]
3. Barnes WJ, Rosen L. Fatal hemorrhagic disease and shock associated with primary dengue infection on a Pacific island. Am J Trop Med Hyg. 1974;23(3):495–506. [PubMed]
4. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet. 1999;354(9188):1431–4. [PubMed]
5. Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, et al. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg. 2006;74(3):449–56. [PubMed]
6. Tang Y, Kou Z, Tang X, Zhang F, Yao X, et al. Unique impacts of HBV co-infection on clinical and laboratory findings in a recent dengue outbreak in China. Am J Trop Med Hyg. 2008;79(2):154–8. [PubMed]
7. Silverman RH. Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol. 2007;81(23):12720–9. [PMC free article] [PubMed]
8. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annual review of biochemistry. 1998;67:227–64. [PubMed]
9. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008;89(Pt 1):1–47. [PubMed]
10. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, et al. High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg. 1993;48(2):222–9. [PubMed]
11. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. 2002;185(9):1213–21. [PubMed]
12. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, et al. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol. 2004;78(6):2701–10. [PMC free article] [PubMed]
13. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, et al. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol. 2000;74(11):4957–66. [PMC free article] [PubMed]
14. Ho LJ, Hung LF, Weng CY, Wu WL, Chou P, et al. Dengue Virus Type 2 Antagonizes IFN-{alpha} but Not IFN-{gamma} Antiviral Effect via Down-Regulating Tyk2-STAT Signaling in the Human Dendritic Cell. J Immunol. 2005;174(12):8163–72. [PubMed]
15. Diamond MS, Harris E. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology. 2001;289(2):297–311. [PubMed]
16. Wati S, Li P, Burrell CJ, Carr JM. Dengue virus (DV) replication in monocyte-derived macrophages is not affected by tumor necrosis factor alpha (TNF-alpha), and DV infection induces altered responsiveness to TNF-alpha stimulation. J Virol. 2007;81(18):10161–71. [PMC free article] [PubMed]
17. Chang TH, Liao CL, Lin YL. Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation. Microbes and infection / Institut Pasteur. 2006;8(1):157–71. [PubMed]
18. Kurane I, Ennis FA. Induction of interferon alpha from human lymphocytes by autologous, dengue virus-infected monocytes. J Exp Med. 1987;166(4):999–1010. [PMC free article] [PubMed]
19. Kurane I, Ennis FA. Production of interferon alpha by dengue virus-infected human monocytes. J Gen Virol. 1988;69(Pt 2):445–9. [PubMed]
20. Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, et al. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol. 2006;177(10):7114–21. [PubMed]
21. Chen RF, Yang KD, Wang L, Liu JW, Chiu CC, et al. Different clinical and laboratory manifestations between dengue haemorrhagic fever and dengue fever with bleeding tendency. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(11):1106–13. [PubMed]
22. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis. 1999;180(5):1429–35. [PubMed]
23. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest. 1991;88(5):1473–80. [PMC free article] [PubMed]
24. Raghupathy R, Chaturvedi UC, Al-Sayer H, Elbishbishi EA, Agarwal R, et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol. 1998;56(3):280–5. [PubMed]
25. Hober D, Poli L, Roblin B, Gestas P, Chungue E, et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg. 1993;48(3):324–31. [PubMed]
26. Juffrie M, van Der Meer GM, Hack CE, Haasnoot K, Sutaryo, et al. Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun. 2000;68(2):702–7. [PMC free article] [PubMed]
27. Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS immunology and medical microbiology. 2001;30(3):229–33. [PubMed]
28. Gagnon SJ, Mori M, Kurane I, Green S, Vaughn DW, et al. Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol. 2002;67(1):41–6. [PubMed]
29. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis. 2004;189(2):221–32. [PubMed]
30. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol. 2006;87(Pt 12):3623–30. [PubMed]
31. Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis. 1998;177(3):778–82. [PubMed]
32. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis. 1999;179(4):755–62. [PubMed]
33. Chakravarti A, Kumaria R. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. The Indian journal of medical research. 2006;123(1):25–30. [PubMed]
34. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et al. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol. 1999;59(3):329–34. [PubMed]
35. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83(8):3719–33. [PMC free article] [PubMed]
36. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol. 2008;80(1):134–46. [PubMed]
37. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, et al. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol. 2007;81(24):13325–34. [PMC free article] [PubMed]
38. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, et al. Role of Dendritic Cells in antibody dependent enhancement of dengue infection. J Virol. 2008;82(8):3939–51. [PMC free article] [PubMed]
39. Yamane A, Nakamura T, Suzuki H, Ito M, Ohnishi Y, et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008;112(3):542–50. [PubMed]
40. Hoarau JJ, Jaffar Bandjee MC, Trotot PK, Das T, Li-Pat-Yuen G, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol. 2010;184(10):5914–27. [PubMed]
41. Her Z, Malleret B, Chan M, Ong EK, Wong SC, et al. Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol. 2010;184(10):5903–13. [PubMed]
42. Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med. 2010;207(2):429–42. [PMC free article] [PubMed]
43. Priyadarshini D, Gadia RR, Tripathy A, Gurukumar KR, Bhagat A, et al. Clinical findings and pro-inflammatory cytokines in dengue patients in Western India: a facility-based study. PLoS ONE. 2010;5(1):e8709. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...